强生在一季度电话会议中强调，最终目标是把cilta-cel推动到一线疗法

（BCMA CAR-T as a first-line therapy）

So, about our BCMA CAR-T that we filed in the first quarter of 2020 that was an important milestone in our pipeline. Our initial indication, it's going to be for patients with multiple myeloma that have progressed on available established therapies.

Over time, we see BCMA CAR-T, and our BCMA CAR-T specifically progressing into earlier lines of therapy. You could see a moment in which young and fit patients may have BCMA CAR-T as a first-line therapy in an intent to build regimens that are curative. Paul?

Paul Stoffels （强生CSO）

Yes. From the beginning, we selected BCMA CAR-T based on its double binding and that has yield a superior profile with -- in the high 90s overall response rates as well as very high MRD-negativity rates and lasting effect. And so, we think this CAR-T is very strongly positioned in the market and hope to get approval in the second half of the year.